Lead Sponsor

Pfizer

Collaborators

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Histologically or cytologically confirmed advanced solid tumors un-responsive to currently available therapies or for which there is no standard therapy.
•At least 1 measurable disease site as defined by Response Evaluation Criterion in Solid Tumors \[RECIST\].
•Adequate bone marrow, liver function and renal function as defined by protocol.
•Blood pressure Requirements During dose escalation - no evidence of pre-existing hypertension and no antihypertensive medications at baseline.
•During dose expansion - patient's whose hypertension is controlled by antihypertensive therapy.

•Chemotherapy, radiotherapy or any investigational therapy within 4 weeks of study entry
•Current use or anticipated need for drugs that are known CYP34 inhibitors or inducers.
•Patients with carcinomatous meningitis or un-treated brain metastases.
•Any acute cardiovascular incident within the past 12 months.
•Patients with active gastrointestinal bleeding or significant gastrointestinal abnormalities as defined by protocol
•Patients with no evidence of the following for 5 years: malignancy or metastatic disease of skin cancer (except melanoma), in situ cervical cancer or breast cancer or T1C prostate cancer.

Related studies

NCT07109154 · Lung Neoplasms

NCT05687123 · Metastatic Pancreatic Neuroendocrine Tumor, Pancreatic Neoplasm, and more

NCT04453072 · Obesity, Malignant Neoplasm

NCT06919965 · Non-Muscle Invasive Bladder Neoplasms

NCT06380816 · Advanced Solid Tumours, Squamous Cell Carcinoma of Head and Neck, and more

A Dose Finding Study Of A New Medication, PF-00337210 That Will Possibly Decrease Blood Supply To Tumors